No Data
No Data
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Stifel Maintains GH Research(GHRS.US) With Buy Rating
Optimistic Outlook for GH Research: Promising Phase 2a Results and Favorable Safety Profile
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
JMP Securities Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $39
Promising Advancements and Strong Financial Position Bolster Buy Rating for GH Research